

Global Implantable Neurostimulation Devices Market Set For 10.9% Growth, Reaching \$13.13 Billion By 2028

The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—for a limited time only!

LONDON, GREATER LONDON, UNITED KINGDOM, December 10, 2024 /EINPresswire.com/ -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!



How Much Has the Implantable Neurostimulation Devices Market Grown Recently?

The implantable neurostimulation devices market size has grown rapidly in recent years. It is



The implantable neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to \$13.13 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%"

The Business Research Company projected to grow from \$7.83 billion in 2023 to \$8.68 billion in 2024 at a compound annual growth rate CAGR of 10.8%. This historical growth period witnessed an increase in demand for non-pharmacological treatments, a surging demand for minimally invasive procedures, an expanding geriatric population, a rise in the array of psychiatric disorders, and an increasing incidence of chronic diseases.

What Is The Future Forecast for the Implantable Neurostimulation Devices Market? The implantable neurostimulation devices market size is poised to experience swift growth in the coming years. It is

forecasted to balloon to \$13.13 billion in 2028, at a CAGR of 10.9%. The growth in the forecast period can be attributed to several factors. These include the rising prevalence of neurological disorders and lifestyle diseases, growing awareness among the population, an increase in spinal cord injuries, and increased healthcare expenditure.

To better understand the recent and upcoming market dynamics, request a sample report: https://www.thebusinessresearchcompany.com/sample.aspx?id=19520&type=smp

What Are The Key Growth Drivers of the Implantable Neurostimulation Devices Market?

The rising prevalence of neurological disorders is expected to propel the growth of the implantable neurostimulation device market going forward. Neurological disorders affect the structure or function of the nervous system, resulting in diverse symptoms such as paralysis, seizures, and cognitive impairments. Increased exposure to risk factors such as high blood pressure, developmental abnormalities, trauma or injury leads to higher detection rates of neurological disorders. Implantable neurostimulation devices, which modulate nerve activity and ameliorate symptoms when other treatments are ineffective or insufficient, are increasingly utilized for treating neurological disorders.

For instance, in 2024, the US-based non-profit voluntary health organization, Alzheimer's Association, estimated that 6.9 million Americans aged 65 and older are living with Alzheimer's disease, with 73% being age 75 or older. This number is predicted to rise to 12.7 million by 2050, thereby driving the growth of the implantable neurostimulation device market.

Get a comprehensive view of the market and its underlying dynamics: https://www.thebusinessresearchcompany.com/report/implantable-neurostimulation-devices-global-market-report

Which Major Companies Are Operating in the Implantable Neurostimulation Devices Market?

Key industry players in the implantable neurostimulation devices market include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Dignity Health, St. Jude Medical LLC, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., Bioness Inc., Saluda Medical Pty Ltd., SceneRay Co. Ltd., NeuroMetrix Inc., CURE Epilepsy, Synapse Biomedical Inc., NeuroSigma Inc., Nuvectra Corporation, MicroTransponder Inc., Pain Management NYC, Curonix LLC.

What Major Trends Are Emerging In The Implantable Neurostimulation Devices Market?

Companies are focusing on developing technologically advanced products, such as spinal cord stimulation SCS systems, to cater to chronic pain conditions. A salient example is the US-based medical device company, Abbott, which announced in December 2022 that the U.S. FDA approved their Eterna spinal cord stimulation SCS system. This advanced device is the market's smallest implantable, rechargeable spinal cord stimulator, engineered for maximum daily comfort.

How Is the Implantable Neurostimulation Devices Market Segmented?

The market report segments the implantable neurostimulation devices market as follows:

1 By Type: Spinal Cord Stimulation SCS, Gastric Electric Stimulation GES, Deep Brain Stimulation DBS, Sacral Nerve Stimulation SNS, Vagus Nerve Stimulation VNS, Other Types

2 By Application: Pain Management, Parkinson's Disease, Urinary And Fecal Incontinence,

Epilepsy, Gastroparesis, Other Applications

3 By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

What Is the Regional Distribution of the Implantable Neurostimulation Devices Market?

In 2023, North America emerged as the largest region in the implantable neurostimulation devices market. However, Asia-Pacific is expected to establish itself as the fastest-growing region in the market during the forecast period. The market report covers various regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company: Neurology Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report Neuroscience Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report Neurotrophic Keratitis Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

You can contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708

ASId +44 20/1930/06

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708

email us here

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/767430371

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.